Achieve Life Sciences (ACHV)
(Delayed Data from NSDQ)
$4.39 USD
-0.04 (-0.90%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $4.38 -0.01 (-0.23%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Achieve Life Sciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 27 | 41 | 33 | 15 | 17 |
Income After Depreciation & Amortization | -27 | -41 | -33 | -15 | -17 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 3 | 2 | 0 | 0 | 0 |
Pretax Income | -30 | -42 | -33 | -15 | -16 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -30 | -42 | -33 | -15 | -16 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -30 | -42 | -33 | -15 | -16 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -27 | -41 | -33 | -14 | -16 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -27 | -41 | -33 | -15 | -17 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 19.83 | 10.59 | 8.12 | 2.72 | 0.41 |
Diluted EPS Before Non-Recurring Items | -1.50 | -4.00 | -4.08 | -5.42 | -39.80 |
Diluted Net EPS (GAAP) | -1.50 | -4.00 | -4.08 | -5.42 | -39.80 |
Fiscal Year end for Achieve Life Sciences, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 8.43 | 5.98 | 4.38 | 6.57 | 7.72 |
Income After SG&A, R&D, and Dept/Amort Expenses | -8.43 | -5.98 | -4.38 | -6.57 | -7.72 |
Non-Operating Income | 0.77 | 0.30 | -0.30 | 0.25 | 0.19 |
Interest Expense | 0.80 | 0.81 | 0.79 | 0.78 | 0.71 |
Pretax Income | -8.46 | -6.49 | -5.48 | -7.11 | -8.24 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -8.46 | -6.49 | -5.48 | -7.11 | -8.24 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -8.46 | -6.49 | -5.48 | -7.11 | -8.24 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 34.32 | 25.05 | 21.17 | 21.13 | 19.05 |
Diluted EPS Before Non-Recurring Items | -0.25 | -0.26 | -0.26 | -0.34 | -0.43 |
Diluted Net EPS (GAAP) | -0.25 | -0.26 | -0.23 | -0.34 | -0.43 |